Tuesday, November 15, 2011

ALS Clinical Trials: Cytokinetics, Neuralstem Advance

CK-2017357 is being tested in combination with riluzole, and Neuralstem will test delivery of its stem cells into the cervical region of the spinal cord

Article Highlights:
  • Two human clinical trials to test experimental therapies in ALS are moving forward.
  • After having tested its experimental therapy CK-2017357 in people with ALS who weren't taking riluzole, biotechnology company Cytokinetics has now begun the second part of its phase 2 trial, in which the two drugs will be tested in combination.
  • Biotherapeutics company Neuralstem will begin testing the safety of transplanting its neural stem cells into the cervical (neck) region of people with ALS.
To learn more, read the full ALS News Online article.